COMPANY PROFILE: COGNIGENICS
Cognigenics is at the forefront of cognitive neuroengineering, spearheading a transformative movement in mental health care. Our mission transcends traditional boundaries, striving not only to mitigate the symptoms of cognitive disorders but also to unlock the potential for augmenting memory and cognitive abilities in healthy individuals. Characterized by meticulous precision, our noninvasive methodologies are designed to yield lasting therapeutic effects, reflecting our commitment to revolutionizing both treatment and enhancement in cognitive health.
Our inaugural products, COG-101 and COG-201 are harnessing cutting-edge gene editing technology, and are poised to address chronic anxiety and MCI. Already, our preclinical studies have yielded encouraging outcomes, demonstrating significant potential in this groundbreaking approach.
We’ve recently completed a successful pre-seed funding round, attracting substantial investments from early-stage backers specializing in mental health and biotechnology. Key investors include Lionheart Ventures, along with other notable supporters. This vital financial boost paves the way for our next crucial stage: securing Seed funding.
The upcoming funding round is pivotal for furthering our research and development efforts. We plan to concentrate on comprehensive dosage and timing studies, rigorously evaluating treatment efficacy variations, and persisting in conducting safety and toxicology assessments. These steps are essential to our pledge of delivering therapies that are both safe and effective.
With an Investigational New Drug (IND) application to the FDA on our horizon, we are gearing up to initiate clinical trials in 2026. This significant step forward is a testament to our commitment to transforming mental health care through avant-garde gene therapy. Our goal extends beyond proving the effectiveness of our approach; we aim to establish a robust foundation for the future landscape of mental health treatments.
Our strategic pipeline is designed to propel our lead asset into clinical stages, while concurrently nurturing the development and enhancement of additional assets, offering broader applications and improved characteristics. Additionally, our R&D pipeline is exploring the creation of RNA-based neurogenetic therapies, targeting conditions such as dementia, anxiety, and depression, thereby expanding our scope in the realm of mental health innovations.